It has been shown that HMA plus VEN increased the overall response rate (ORR) to 76% in R/R AML, and in subgroup analysis of IDH1/2 mutated AML, the ORR reached 82%, showing the importance of these mutations and their effect regarding the response to the HMA/VEN combination. The gene discussed is IDH1; the disease is acute myeloid leukemia.